Manidipino Combix (Manidipine Dihydrochloride)

• Manidipine is used as an antihypertensive agent that lowers blood pressure by targeting vascular smooth muscle.
• Hypertension: Reduces systolic and diastolic blood pressure in patients with essential hypertension, improving overall cardiovascular risk management.

• Manidipine selectively blocks L‑type calcium channels located on vascular smooth‑muscle cells. By preventing calcium influx, it inhibits smooth‑muscle contraction, causing arterial vasodilation. The resulting decrease in peripheral vascular resistance lowers systemic blood pressure without significant effect on cardiac conduction or contractility, making it effective for managing essential hypertension. The drug’s high affinity for L‑type channels provides a sustained antihypertensive effect with a favorable pharmacokinetic profile, allowing once‑daily dosing in most patients.

Manidipine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often occurring shortly after dosing.
• Flushing: transient warmth and redness of the skin.
• Peripheral edema: swelling of the ankles or lower legs.
• Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure that may cause fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Allergic reactions: including rash, itching, or anaphylaxis in susceptible individuals.

Before initiating therapy, clinicians should evaluate individual patient factors and monitor for potential adverse events.

• Monitor blood pressure: adjust therapy based on response and tolerability.
• Assess liver function: use with caution in patients with hepatic impairment.
• Caution in elderly: increased sensitivity to blood‑pressure‑lowering effects.
• Avoid abrupt discontinuation: taper dose to prevent rebound hypertension.
• Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Manidipine can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations.
• Concomitant use with other antihypertensives: can cause excessive hypotension.
• Grapefruit juice: may elevate drug levels and risk of side effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.
• Non‑steroidal anti‑inflammatory drugs: may increase risk of renal impairment.
• Beta‑blockers: additive blood‑pressure‑lowering effect requiring dose adjustment.